Browse MPDU1

Summary
SymbolMPDU1
Namemannose-P-dolichol utilization defect 1
Aliases SL15; Lec35; PQLC5; CDGIf; HBEBP2BPA; My008; PP3958; HBeAg-binding protein 2 binding protein A; suppressor o ......
Chromosomal Location17p13.1-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein
Domain PF04193 PQ loop repeat
Function

Required for normal utilization of mannose-dolichol phosphate (Dol-P-Man) in the synthesis of N-linked and O-linked oligosaccharides and GPI anchors.

> Gene Ontology
 
Biological Process GO:0006457 protein folding
GO:0006488 dolichol-linked oligosaccharide biosynthetic process
GO:0006490 oligosaccharide-lipid intermediate biosynthetic process
GO:0009311 oligosaccharide metabolic process
GO:0009312 oligosaccharide biosynthetic process
GO:0016051 carbohydrate biosynthetic process
GO:0044723 single-organism carbohydrate metabolic process
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-446193: Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
Summary
SymbolMPDU1
Namemannose-P-dolichol utilization defect 1
Aliases SL15; Lec35; PQLC5; CDGIf; HBEBP2BPA; My008; PP3958; HBeAg-binding protein 2 binding protein A; suppressor o ......
Chromosomal Location17p13.1-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MPDU1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMPDU1
Namemannose-P-dolichol utilization defect 1
Aliases SL15; Lec35; PQLC5; CDGIf; HBEBP2BPA; My008; PP3958; HBeAg-binding protein 2 binding protein A; suppressor o ......
Chromosomal Location17p13.1-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MPDU1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMPDU1
Namemannose-P-dolichol utilization defect 1
Aliases SL15; Lec35; PQLC5; CDGIf; HBEBP2BPA; My008; PP3958; HBeAg-binding protein 2 binding protein A; suppressor o ......
Chromosomal Location17p13.1-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MPDU1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0690.782
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4990.843
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2420.899
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7650.0217
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3670.781
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2760.49
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0690.847
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0420.979
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1540.933
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0230.991
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0610.986
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0460.472
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MPDU1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMPDU1
Namemannose-P-dolichol utilization defect 1
Aliases SL15; Lec35; PQLC5; CDGIf; HBEBP2BPA; My008; PP3958; HBeAg-binding protein 2 binding protein A; suppressor o ......
Chromosomal Location17p13.1-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MPDU1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMPDU1
Namemannose-P-dolichol utilization defect 1
Aliases SL15; Lec35; PQLC5; CDGIf; HBEBP2BPA; My008; PP3958; HBeAg-binding protein 2 binding protein A; suppressor o ......
Chromosomal Location17p13.1-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MPDU1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MPDU1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMPDU1
Namemannose-P-dolichol utilization defect 1
Aliases SL15; Lec35; PQLC5; CDGIf; HBEBP2BPA; My008; PP3958; HBeAg-binding protein 2 binding protein A; suppressor o ......
Chromosomal Location17p13.1-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MPDU1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMPDU1
Namemannose-P-dolichol utilization defect 1
Aliases SL15; Lec35; PQLC5; CDGIf; HBEBP2BPA; My008; PP3958; HBeAg-binding protein 2 binding protein A; suppressor o ......
Chromosomal Location17p13.1-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MPDU1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMPDU1
Namemannose-P-dolichol utilization defect 1
Aliases SL15; Lec35; PQLC5; CDGIf; HBEBP2BPA; My008; PP3958; HBeAg-binding protein 2 binding protein A; suppressor o ......
Chromosomal Location17p13.1-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MPDU1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMPDU1
Namemannose-P-dolichol utilization defect 1
Aliases SL15; Lec35; PQLC5; CDGIf; HBEBP2BPA; My008; PP3958; HBeAg-binding protein 2 binding protein A; suppressor o ......
Chromosomal Location17p13.1-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MPDU1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.